'Unreasonable' prescription drug costs; high prices and broken promises

14 September 2018
drugpricing-big

The USA spends about $3.3 trillion a year on health care, with about 10% of that spending for prescription drugs. Most Americans are very concerned about the high cost of prescription drugs.

Three-quarters of Americans consider the cost of prescription drugs in the USA to be "unreasonable," and despite promises from the President and members of Congress to rein in prices, few approve of either's handling of the issue, according to a new national poll from the West Health Institute, a non-partisan, non-profit healthcare research organization, and conducted by NORC at the University of Chicago.

Only 23% of the public approves of how President Donald Trump is dealing with the high cost of prescription drugs. Nor are Americans satisfied with how either party in Congress is handling the issue: 20% approve of what Democrats in Congress are doing and 16% approve of how Republicans are handling the issue. Roughly a third of respondents had no opinion either way.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical